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The effects of a range of environmental
mutagens in terms of the kinds of
mutations they induce and how these are
repaired by the cell is presented in the
form of a resource.
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Whole-genome-sequencing (WGS) of human tumors
has revealed distinct mutation patterns that hint at
the causative origins of cancer. We examined muta-
tional signatures in 324WGS human-induced pluripo-
tent stem cells exposed to 79 known or suspected
environmental carcinogens. Forty-one yielded char-
acteristic substitution mutational signatures. Some
were similar to signatures found in human tumors.
Additionally, six agents produced double-substitution
signatures and eight produced indel signatures.
Investigating mutation asymmetries across genome
topography revealed fully functional mismatch and
transcription-coupled repair pathways. DNA dam-
age induced by environmental mutagens can be
resolved by disparate repair and/or replicative path-
ways, resulting in an assortment of signature out-
comes even for a single agent. This compendium of
experimentally inducedmutational signatures permits
further exploration of roles of environmental agents in
canceretiologyandunderscoreshowhumanstemcell
DNA is directly vulnerable to environmental agents.
INTRODUCTION
English physicians of the 18th century are credited with linking
environmental exposures to cancer. They observed an increased
incidence of nasal polyps among users of snuff and associated
scrotal cancer in chimney sweeps with chronic exposure to
soot (Brown and Thornton, 1957). A century later, public health
recommendations for frequent bathing for sweeps had seen
the virtual eradication of scrotal cancer among sweeps in main-
land Europe, but not in England, where bathing frequency re-
mained low (Butlin, 1892). Subsequent associations between
environmental agents and tumorigenesis include tobacco smok-Cell 177, 821–836
This is an open access article unding and lung cancer, aniline dyes and bladder cancer, asbestos
and mesothelioma, aflatoxin and liver cancer, and benzene and
leukemia (Pfeifer et al., 2002; Walker and Gerber, 1981; Yang,
2011). The public health impact of understanding these associa-
tions is significant; identifying causes of cancer is essential for
effective preventative interventions.
Although mechanisms underpinning how environmental car-
cinogens cause cancer are not fully understood, many cause
DNA damage that results in mutations, as demonstrated exper-
imentally in reporter genes (e.g., lacZ) and cancer-related genes
(e.g., RAS and TP53) (DeMarini et al., 2001; Giglia-Mari and Sar-
asin, 2003; Pfeifer, 2000; Zhivagui et al., 2017). Specific patterns
associated with exposure to particular carcinogens have been
identified in TP53 in human cancers too (Hollstein et al., 1991;
Olivier et al., 2010), revealing that codon position, sequence
context, and strand bias can be tumor-type- and carcinogen-
specific. For instance, lung tumors from smokers harbor C >
A/G > T transversion mutations in TP53 codons 157, 158, 245,
248, and 273 (Pfeifer, 2000). Further, guanines at these codons
were preferentially adducted and mutated in cells treated with
benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE), a reac-
tive metabolite of the polycyclic aromatic hydrocarbon (PAH)
benzo[a]pyrene (BaP) from tobacco-smoke in human (Denis-
senko et al., 1996) and mouse embryo fibroblast (MEF) models
(Kucab et al., 2015). Additionally, G > T transversions induced
in vitro and those in lung cancers exhibit a strong transcriptional
strand bias. This is believed to reflect transcription-coupled
nucleotide excision repair (TC-NER) of bulky adducts formed
by tobacco carcinogens (Hainaut and Pfeifer, 2001).
Similar observations were made with other environmental ex-
posures. UV light induces C > T/G > A and CC > TT/GG > AA
transitions in DNA reflecting the formation of pyrimidine dimers
(Pfeifer et al., 2005). This was corroborated by observations in
UV-associated squamous and basal cell carcinomas and malig-
nantmelanomas. Aristolochic acid I (AAI), a phytochemical asso-
ciated with urothelial cancer development (Nedelko et al., 2009),
induces A > T/T > A transversions in vitro, as found in TP53 in
AAI-treated Hupki MEFs, mimicking the mutational spectra
seen in urothelial tumors from patients exposed to aristolochic, May 2, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 821
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
acid (Nedelko et al., 2009; Stiborová et al., 2016). These studies
based on single gene analyses are highly informative but are
limited by the fact that only a single mutation per sample was
incorporated into each dataset.
Today, technological improvements permit whole genomes
to be sequenced in a single experiment. Whole-genome
sequencing (WGS) of a single malignant melanoma and a single
lung cancer cell line first illustrated the power of this approach
(Pleasance et al., 2010a, 2010b), revealing the characteristic
mutational spectra of UV light and tobacco carcinogens, respec-
tively. Subsequently, WGS of large numbers of other tumors re-
vealed mutational patterns (Nik-Zainal et al., 2012a, 2012b) in
nearly all tumors (Alexandrov et al., 2013; Helleday et al., 2014)
that arise from both endogenous and exogenous sources (Helle-
day et al., 2014; Nik-Zainal et al., 2016). Global, unbiased depic-
tion provided by WGS has permitted more refined insights into
mutational processes of human cancers, facilitating clinical
applications of cancer genomics (Berger andMardis, 2018; Mar-
dis and Ladanyi, 2016).
Human cancers, however, result from environmental and
endogenous exposures that are uncontrolled and in highly vari-
able genetic backgrounds. Although mathematical methods
have been applied to deconstruct mutation profiles into individ-
ual mutational signatures, these approaches are complex and
fraught with issues of interpretation due to lack of experimental
controls (Nik-Zainal and Morganella, 2017).
An important next step, therefore, is to systematically examine
mutational patterns associated with a broad selection of envi-
ronmental or therapeutic mutagens, generated under highly
controlled conditions. We used a human induced pluripotent
stem cell (iPSC) line, having the advantages of being normal,
undifferentiated, fast-growing, and easy to clone. Most of the
agents tested are classified by the International Agency for
Research on Cancer as known, probable, or possible human
carcinogens (group 1, 2A, and 2B, respectively). We present a
first comprehensive assessment that we hope will serve the
community in due course.RESULTS
This study included 77 chemical carcinogens, therapeutic
agents, or DNA damage response (DDR) inhibitors, 2 sources
of radiation, and a range of controls. These diverse agents dam-
age DNA in various ways and may be repaired by different path-
ways. We assessed cytotoxicity and functional DDR readouts,
subsequently generating a series of treated and control parental
cell cultures (128 in total). From these, we derived single-cell
daughter subclones (324 in total) and examined mutational
patterns by WGS (Figure 1).Cytotoxicity and DNA Damage Response
To standardize treatment regimens, we used a concentration or
dose for each agent that caused 40%–60% cytotoxicity,
measured 72 h after treatment. For some treatments (n = 19), a
higher concentration causing >80% cytotoxicity was also used
(Table S1). Most chemicals had an IC50 in the mM range; 15
were in the mM range and 23 were sub-mM (Figure 1; Table S1).822 Cell 177, 821–836, May 2, 2019Many compounds require metabolic activation into reactive
intermediates to exert DNA damaging effects, often via cyto-
chrome P450 enzymes. Because metabolic competence of
iPSCs has not been established, 28/77 agents were tested
with inclusion of S9 rodent liver-derived metabolic enzyme
mixture.
Induction of phosphorylation or expression of four DDR pro-
teins was examined: phospho-CHK2, phospho-p53, p21, and
g-H2AX (Figure S1; Table S1). Sixteen of 113 treatment condi-
tions (e.g., formaldehyde, catechol, acrolein) failed to induce
detectable DDR signaling markers. Two of the 16 were associ-
ated with a mutation pattern (formaldehyde and 1,2-dimethylhy-
drazine [1,2-DMH] +S9). Of remaining treatments that induced
one or more DDRmarkers, 51/97 were associated with mutation
patterns. Intriguingly, acetaldehyde, N-methyl-N0-nitro-nitroso-
guanidine (MNNG), and acrylamide induced DDR, but not
detectable mutation patterns. Thus, the ability to induce DDR
was not necessarily indicative of mutagenic potential.
Identifying Mutational Signatures
A total of 324 subclones were derived from 128 control and
mutagen-treated cultures; 62 had two subclones, 64 had three
subclones and 2 had four subclones (Table S2). All were suc-
cessfully sequenced to 30-fold depth. Short-read sequences
were aligned to human reference genome assembly GRCh37/
hg19. All classes of somatic mutations were called in subclones
subtracting on the primary iPSC parental clone.
To ensure that the iPSC model remained stable and did not
develop overt malignant potential, we evaluated chromosomal
copy number in all 324 subclones. All remained diploid, un-
changed from their parent. We looked for evidence of selection,
including clonal and subclonal mutations in all DNA repair genes
and in TP53, and for driver amplifications in all samples. None
were identified. To ensure that we had comparable WGS data
not arising from mixed populations, all experimental single-cell
bottlenecks were monitored using an IncuCyte (Figure S2).
Variant allele fraction distributions for all subclones were exam-
ined (STAR Methods) giving confidence that each mutational
profile came from a single cell.
Common culture reagents could generate mutational signa-
tures and potentially confound interpretation of mutagen treat-
ments. Thus, we included fifteen control clones treated with sol-
vent concentrations matching those of the mutagen-treated
samples; two were treated with water, three with culture media
(one +S9 and two S9), one with sodium chloride (0.003%),
two with dimethylsulfoxide (DMSO) (at 0.68% and 0.1%), one
with hamster S9 and 0.5% DMSO, four with rat S9 mix and
DMSO at different concentrations (0.5%, 0.35%, and two at
0.1%), and two with methanol (4.3% with rat S9 and 1.3%
without S9). All controls had a similar signature and level
of background mutagenesis (245 substitutions, 1 double
substitution,10 short insertions/deletions [indels], and0 rear-
rangements per genome) (Figure 2; Tables S2 and S3).
Background mutagenesis has been reported in other human
cellular systems (Behjati et al., 2014; Rouhani et al., 2016) and
attributed to DNA damage incurred during cell culture.
Additional mutagenesis above background was variable be-




Figure 1. Experimental Protocol and Mutagen Information
(A) Assessment of cytotoxicity and DNA damage response to identify effective concentrations.
(B) Experimental workflow.
(C) Schematic showing how a mutagen-associated mutational process changes a mutational profile.
(D) List of mutagens and their treatment conditions.
See also Figure S1 and Table S1.of the same treatment (Figures 2A–2C). To ensure systematic,
robust signature discovery, we defined the ubiquitous back-
ground signature based on control samples and ensured that
the total number of mutations for any given treatment was signif-
icantly greater than the controls (q value <0.01, permutation
test). An index of mutagenicity was calculated to quantify effect
size ofmutagenesis over background (Figure 2D).We next deter-
mined if the mutational profile of a treatment was compellingly
dissimilar to the background signature (signal-to-noise-ratio
[SNR] > = 2; STAR Methods). Finally, we calculated a ‘‘stability’’measure that penalizes excessive variation between subclones
for a given treatment. This highly conservative additional step
separates signatures of which we are strongly confident from
those likely to be present but that we have less confidence in.
For treatments that we considered had associated mutational
signatures, the background culture-associated signature (Fig-
ure 3A) was subtracted, leaving a putative treatment signature
(Figure 3B for substitutions; STAR Methods). To ensure that
experimentally generated signatures were not due to a DNA
repair defect acquired during culture, we searched for codingCell 177, 821–836, May 2, 2019 823
A B C D
Figure 2. Mutation Frequencies
(A–C) De novo mutation numbers identified for substitutions (A), double-substitutions (B), and indels (C). Asterisks indicate a significant increase in mutations
over controls (STAR Methods). **q value % 0.01; ***q value % 0.001 (permutation test). Data are for 2–4 independent subclone experiments. Bars represent
mean ± SEM of subclone observations.
(D) For treatments with a significant increase in mutations, mutagenicity index = (Ntreatment  Ncontrol)/Ncontrol, where Ntreatment is the average mutation number of
treatment subclones and Ncontrol is the average mutation number of control subclones.
See also Tables S2 and S3.sequencemutations in subclones that could potentially influence
mutational outcomes and found none of consequence.
Of 113 treatment conditions involving 79 agents, approximately
half induced additional numbers of substitutions and/or double-
substitutions and/or indels, clearly different to controls (Figure 2).
The numbers of rearrangements and copy number aberrations
were limited and not informative. 53 putative single-base substitu-
tion mutational signatures were observed from 41 agents (Fig-
ure3B), alongwith8double-substitution (Figure4) and10 indel sig-
natures (Figure 5). Thus, distinct mutational signatures were seen
for 52%ofagents tested (Figures2Dand6A;TableS2)withseveral
producing more than one class of signature (Figure 6A).
Substitution Mutational Signatures of Environmental
Mutagens
Our experiments detected some well-known mutational signa-
tures. Simulated solar radiation (SSR) (Figure 3B) recapitulated
the signature observed in UV-associated cancers (cosine simi-
larity [henceforth cossim] 0.94) (Figure S3A) and UV-treated
MEFs (Nik-Zainal et al., 2015) with 91% of SSR-induced substi-824 Cell 177, 821–836, May 2, 2019tutions being C > T/G > A transitions in our study. The mutational
signature induced by AAI (Figure 3B) recapitulated that seen in
urothelial cancers associated with aristolochic acid exposure
(cossim 0.99) (Figure S3A) and in AAI-treated MEFs, dominated
by A > T/T > A transversions.
28 mutagens were tested +S9, 13 of which were also tested
S9. Of the 15 tested +S9 only, 10 had signatures: 2-amino-
1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), cyclophospha-
mide, dibenz[a,h]anthracene (DBA), BaP, 5-methylchrysene,
dibenz[a,j]acridine (DBAC), furan, 4-aminobiphenyl (4-ABP),
aflatoxin B1 (AFB1), and ochratoxin A (OTA). Of 13 compounds
tested, both +S9 and S9, 6-nitrochrysene and dibenzo[a,l]
pyrene (DBP) had signatures both ways, while 5 did not
have signatures irrespective of state of metabolic activation
(2-naphthylamine, 2,6-dimethylaniline, 4,40-methylene(2-chlor-
oaniline) [MOCA], 7H-dibenzo[c,g]carbazole [DBC] and o-anisi-
dine). Three agents had signatures only when tested +S9
(1,2-DMH, ellipticine, 3-chloro-4-(dichloromethyl)-5-hydroxy-
2(5H)-furanone [MX]). Benzidine, methyleugenol, and semustine
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consistent impact of including an exogenous metabolizing sys-
tem on mutagenesis; outcomes were compound-specific.
When a higher treatment concentration was also tested, 9
agents had near-identical signatures at both concentrations:
1,8-dinitropyrene (1,8-DNP), 3-nitrobenzanthrone (3-NBA), 6-ni-
trochrysene, BaP, dibenz[a,h]anthracene diol-epoxide (DBADE),
dibenzo[a,l]pyrenediol-epoxide (DBPDE), PhIP, cisplatin, andpo-
tassium bromate. Three agents had slightly different outcomes at
either concentration: cyclophosphamide, 4-ABP, and formalde-
hyde. For 6 compounds, higher concentration resulted in more
mutations: DBADE, DBPDE, 1,8-DNP, 3-NBA, 6-nitrochrysene,
and cisplatin. Six agents did not induce mutational signatures at
either of two concentrations: 2-naphthylamine, 2-nitrofluorene,
2,6-dimethylaniline, acetaldehyde, nickel chloride, and DBC.
Next, we compared the 53 mutagen-induced substitution
signatures by unsupervised hierarchical clustering of the
96-element profiles (Figure 3C). Reassuringly, several com-
pounds with treatments performed at different concentrations
clustered together, reflecting highly similar mutational profiles
from independent experiments and the robustness of the system
(e.g., 6-nitrochrysene, PhIP, 1,8-DNP, 3-NBA, and potassium
bromate). Different compounds within the same family group
bore likeness in mutational profile and clustered together (e.g.,
the alkylating agents temozolomide, N-methyl-N-nitrosourea
(MNU), and N-ethyl-N-nitrosourea (ENU) and the platinum com-
plexes cisplatin and carboplatin). Of interest, signatures of three
PAHs, BaP, DBA, and DBP, bore closer similarity to those of their
diol-epoxide metabolites (BPDE, DBADE, and DBPDE, respec-
tively) than to each other.
There were also some surprises. DBP and DBPDE clustered
closely with AAI. On closer inspection, there were striking similar-
ities in the peaks of the T > A/A > T component between these
different compounds reflecting a commonality in adduct formation
atadenine residuesby thesedisparatemutagens. InAAI, this trans-
version mutation accounted for 83% of the signature, whereas for
DBP and DBPDE it amounted to 53%–70% of the total mutations.
Thus importantly, different adducts can leave similar mutagenic
imprints even when the primary mutagens are unrelated.
Environmental Mutagens Cause DNA Damage Affecting
Neighboring Nucleotides
Double-substitutions could arise due to two independent events
occurring by chance at sites next to each other or when muta-
genic damage at a site is linked to damage at the adjacent
site. The latter is the case for CC > TT mutations caused by UV
where modifications involving tandem pyrimidines result in
6,4-PPs and CPDs, as seen in TP53 gene assays in vitro and in
tandem BRAF mutations in malignant melanomas (Thomas
et al., 2004).
The frequency of double-substitutions in our dataset (Fig-
ure 2B; Table S3) was higher than expected. To understandFigure 3. Substitution Signatures
(A) Mutational profile of all controls. It is a 96-channel vector (6 types of substitutio
also the background signature seen in all treatments.
(B) Signatures identified from 53 treatments. Blue indicates a less stable signatu
(C) Hierarchical clustering of the 53 signatures.
See also Figure S3 and Table S4.
826 Cell 177, 821–836, May 2, 2019whether they arose because of elevated mutagenesis or
because of the specific pattern of a given treatment, we per-
formed simulation experiments correcting for mutation density
and trinucleotide preponderance of experimentally induced
mutational signatures and taking frequency of trinucleotides in
the reference genome into account. The likelihood of observing
even one double-substitution is small (Figure 4A). Thus, the
model of two chance events causing double-substitutions is
much less likely than one that postulates that there is an
increased likelihood of affecting the mutability of the immediate
neighboring base. Furthermore, we observed double-substitu-
tions across all subclones of all treatments at a frequency higher
than expected from the simulation experiments, including in
control samples (Figure 2B). Thus, there may be a universal
stressor increasing the likelihood of double-substitutions in
the iPSCs.
Six agents (8 treatments) had statistically significant differ-
ences in double-substitution frequency compared with control
(Figure 4B). Their patterns were diverse (Figures 4C and 4D).
SSR was associated with a distinctive CC > TT pattern, in keep-
ing with previous reports, constituting 6% of the total substitu-
tion burden in treated samples. Some of the PAHs (BPDE,
DBA, and its metabolite, DBADE) tended to generate mainly
CC > AA/GG > TT, but also CA > AT/TG > AT mutations
(Figure 4C). Platinum compounds produced an AG> TT predom-
inance, with GA > TT also observed (mainly restricted to
cisplatin).
Double-substitutions were more likely to produce a TT
outcome in all of the signatures identified (Figure 4C). This sug-
gests that, regardless of primary DNA adduct, the most likely
misreplication process that results in fixation of double-substitu-
tions follows Strauss’ A-rule (Strauss, 2002), where A is inserted
opposite an uninformative site, resulting in a subsequent T-fixed
mutation. In conclusion, damage caused by particular environ-
mental mutagens does have an effect on neighboring nucleo-
tides. Whether these mutagens increase the likelihood of DNA
adduct formation at adjacent nucleotides or increase the likeli-
hood of erroneous repair of their neighbors is unclear.
Environmental Mutagens Cause DNA Damage Resulting
in Indel Signatures
Small indels (<100 bp) and substitutions arise through different
mutational mechanisms. A model of strand slippage in repetitive
DNA sequences creating misaligned intermediates with un-
paired nucleotide loops was posited to be the preliminary step
in indel formation (Fresco and Alberts, 1960; Streisinger et al.,
1966; Streisinger and Owen, 1985). This is governed by post-
replicative DNA mismatch repair (MMR) (Kunkel and Erie,
2005; Modrich and Lahue, 1996), reflected in excessively high
1–2 bp indelmutagenesis at polynucleotide repetitive sequences
when MMR is inactivated (Greene and Jinks-Robertson, 1997;n * 4 types of 50 base * 4 types of 30 base). Mean ± SEM of 35 subclones. This is




Figure 4. Double-Substitution Signatures
(A) Expected probability of formation of a double-
substitution by two random substitutions.
(B) Hierarchical clustering of eight aggregated
double-substitution profiles (treatments with
double-substitution number > 20). The first mu-
tation represents 50 base change, the second
mutation represents 30 base change. In total, there
are 78 types of double-substitutions (STAR
Methods).
(C) Double-substitution profiles as bar plots. Blue
indicates a less stable signature.
(D) Cosine similarities between eight double-
substitution signatures.
See also Table S6.Tran et al., 1997) such as in colorectal carcinomas (Ionov et al.,
1993; Thibodeau et al., 1993). By contrast, larger indels
(R3 bp in motif size) were noted to be enriched in cancers with
mutations in BRCA1/BRCA2 (Nik-Zainal et al., 2012a). These in-
dels showed a small amount of homology between the indel
motif and the flanking sequence, termed microhomology. The
number of bases involved in microhomology was greater than
expected by chance and believed to be the footprint of alterna-
tive non-homologous end joining (alt-NHEJ) double strand break
(DSB) repair processes compensating for defective homologousrecombination (HR) repair in tumors that
are BRCA1/BRCA2-deficient. To call
upon alt-NHEJ, the DNA damage step
must have involved generation of one or
more DSBs, thus representing an entirely
different mutational process than that
generating small indels at the polynucle-
otide tracts.
Analyses of indel mutagenesis have
since taken flanking sequence character-
istics into account. As many of the com-
pounds used here have a preponderance
to affect guanines, we extended indel
classification to take nucleotide types
into account. We categorized indels by
class (deletion versus insertion), motif
CG/TA content and size (1 bp or larger),
CG/TA content of flanking sequence,
and length of repetitive sequence if the
motif was flanked by polynucleotide re-
peats. A microhomology-mediated cate-
gory was restricted to deletions only. This
resulted in 29 channels for indel signature
discovery (Figure 5A and S4 for control
indel profile; STAR Methods).
Indel signatures were obtained with
6 agents (8 treatments) (Figure 5B).
1,2-DMH had a unique preponderance
for C deletions flanked by T nucleotides.
In contrast, 1,8-DNP and 3-NBA, both
nitro-PAHs, had near-identical indel sig-
natures (Figure 5B), characterized by Cdeletions at long repetitive tracts and larger deletions (e.g.,
2 bp and 3 bp motifs) at di- or tri-nucleotide repeat tracts.
Another nitro-PAH, 6-nitrochrysene, had a more mixed indel
phenotype. Cisplatin produced a mutational signature charac-
terized by T insertions at single T or long tracts of repetitive
Ts. These T insertions were just downstream of GpG dinucleo-
tides (Figure 5C). This is in keeping with a previous report
(Szikriszt et al., 2016) and is highly interesting because GpG
dinucleotides are the targets of intrastrand crosslinks of plat-




Figure 5. Indel Signatures
(A) Indel profile of controls. Due to low numbers, all control subclones are aggregated to obtain a more accurate indel profile (see Figure S4).
(B) Profiles of eight mutagens (10 treatments). Blue indicates less stable signature.
(C) High resolution profile of cisplatin (12.5 mM)-induced one-base T insertion in repetitive sequence, taking 50 sequence context into account.
(D) High resolution profile of DBADE-induced T and C insertions.
(E) Cosine similarities between ten mutagen, smoking-associated lung, and control signatures.
See also Figure S4 and S5.Among the PAHs, BaP, BPDE, and DBADE had strong resem-
blances to the indel signature extracted from smokers’ lung
cancers (Figure 5E). BaP had an indel signature defined by dele-
tions of C specifically at C repetitive sequences of <3 bp (i.e.,828 Cell 177, 821–836, May 2, 2019C flanked by C or CC), nearly identical to its diol-epoxide,
BPDE (cossim 0.95, Figure 5E). DBA also had an excess of C
deletions at repeat sequences <3 bp but did not get called as
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showed an additional component of T insertions at single T
nucleotides. Inspection of surrounding sequence downstream
of the single 30 T revealed a propensity to occur at G runs (Fig-
ure 5D). It is interesting to consider that repair of an adducted
guanine could result in an indel in its vicinity. Last, DBADE had
a stronger mutagenicity index for forming indels than substitu-
tions over background, similar to its parent compound DBA
(Figure 2D).
Thus, DNA damage induced by particular agents can be asso-
ciated with multiple mutational signatures of different classes
(Figures 2D and 6A). The diversity of mutational outcomes
observed for some mutagens is likely to be due to different
mechanisms of resolving a particular type of damage (e.g., a
cisplatin intrastrand crosslink), whichmay involve different trans-
lesion polymerases.
Mutational Signatures Derived from PAHs
PAHs are considered to be among the most significant muta-
genic components of tobacco smoke. Of the fourteen treat-
ments involving PAHs and related metabolites, all were
associated with signatures apart from DBC (Figures 3B and
6A; Table S4).
BaP, DBA, and DBP clustered closer to their respective diol-
epoxides than to one another in the hierarchical-clustering exer-
cise. Although several mechanisms have been proposed for how
PAHs exert their biological effects (IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans, 2010), the close
similarity between the signatures of parent PAHs and their
respective diol-epoxides is powerful evidence that the diol-
epoxide pathway of metabolic activation is responsible for the
mutagenic activity of the PAH class in mammalian cells. For
BaP and BPDE, a high proportion of the mutations are at G:C
pairs, and most are G > T/C > A, reflecting how their DNA ad-
ducts are formed principally at N2-guanine. Concordant with
previous reports, the propensity for guanine damage is particu-
larly elevated at methylated CpGs (p value < 0.01, Fisher exact
test). In contrast, DBP and DBPDE signatures contain a majority
of mutations at A:T, consistent with predominant DNA adduct
formation at the N6-adenine.
5-Methylchrysene is activated via a diol-epoxide that reacts
with guanine. 90% of its mutations are at G:C, mainly G > T/C
> A (71%), with greatest similarity to DBA/DBADE (cossim 0.95
and 0.97, respectively). The distinguishing feature of the G >
T/C > A transversions induced by these compounds is that the
tallest peak is at CpCpT, followed by CpCpC. By contrast, for
BaP and BPDE, the tallest G > T/C > A peak occurs at CpCpC
followed by CpCpT. DBAC, which has a nitrogen atom in one
of its 6-membered rings, clustered separately from the other
PAHs and is most similar to 3-NBA, a nitro-PAH. Its signatureFigure 6. Mechanisms of Mutagen-Associated Mutational Signatures
(A) Summary of mutagen-associated signatures. Light blue indicates an unstable
(B) Sequence context of BaP, BPDE, DBA and DBADE substitution and indel mut
Pathways to BaP, BPDE, DBA, and DBADE mutations are shown.
(C) Progression to mutation by five alkylating agents.
(D) Proposed mechanisms underpinning 1,2-DMH substitution and indel signature
bases increases the probability of G mutating. Lower diagram: how signatures ca
pairs with T leading to a G > A substitution; in the right-hand branch, slippage ad
830 Cell 177, 821–836, May 2, 2019comprises mainly G:C mutations (70%), of which 52% are G >
T/C > A transversions.
Four compounds had significantly elevated numbers of substi-
tutions, double-substitutions, and indels: BaP, BPDE, DBA, and
DBADE. Each of these classes of signatures occurred at tracts of
CC or CCC (equivalent to GG or GGG) (Figure 6B and S5). Thus,
the primary DNAdamaging step is adduct formation at short runs
of guanines, but resolution of that damage, by the replicative
A-rule, MMR and/or TC-NER, underpins the different final
imprints (Figure 6B).
Mutational Signatures Associated with Free Radicals
Free radical species induce a number of DNA lesions, the most
abundant being 8-oxo-G, which can create G > T/C > A transver-
sions, particularly at runs of consecutive guanines. Although
hydrogen peroxide, anticipated to create ROS, and peroxyni-
trite, which generates reactive nitrogen (nitric oxide) species,
did not yield clear mutation patterns, potassium bromate that
generates hydroxyl radicals did show enrichment for G > T/C >
A mutations (88%) in two independent experiments (260 mM
and 875 mM). Its signature clusters separately but bears closest
similarity to the cluster that includes the background signature
that is similar to COSMIC Signature 18 (Figure S3A), reported
to be due to ROS. Ochratoxin A and methyleugenol also clus-
tered in this group, and their signatures may reflect an enhanced
production of ROS (Figures 3C and S3A).
Mutational Signatures of Alkylating Agents
Alkylating agents add an alkyl group (CnH2n+1) to DNA. O
6-alkyl-
guanine causes G >A/C > T, O4-alkylthymine causes T >C/A >G
and O2-alkylthymine causes T > A/A > T, while N-alkylpurines
(N7-dG and N3-dA) can give rise to apurinic sites (Jenkins
et al., 2005) (Figure 6C).
Eight alkylating agents were examined (9 treatments overall—
1,2-DMH was assessed +S9 and S9). 1,2-DMH (S9), methyl-
methanesulfonate (MMS), and MNNG were not associated with
significant mutational patterns. MMS subclones had total
numbers of mutations slightly above background but a nonde-
script mutational profile, not distinctive enough to be detected
as a signature. MNNG has been reported to produce a charac-
teristic C > T/G > A mutation pattern in MEFs (Olivier et al.,
2014), but we did not see a signature in either of its subclones.
Five alkylating agents producedmutation patterns clustered in
two distinct groups (Figure 3C). ENU andMNU clustered with te-
mozolomide (listed as a drug therapy but is also an alkylating
agent) with signatures dominated by T > C/A > G transitions
(85%, 50%, and 78% respectively) and highly correlated with
one another (cossims: temozolomide versusMNU 0.98, temozo-
lomide versus ENU 0.84; MNU versus ENU 0.85). The othersignature (subclone variation); dark blue indicates a stable signature.
ation patterns. Substitutions and indels are more likely to occur near CC (GG).
s. 1,2-DMH alkylates Gs particularly at ApG sites. An increasing number of 50A
n arise for 1,2-DMH: in the left-hand branch, O6-meG in a (polyA)pG sequence
ditionally occurs resulting in a loss of T.
group comprising diethyl sulfate (DES) and dimethyl sulfate
(DMS) additionally had C > T/G > A transitions (40% and 29%,
respectively) and were similar to each other (cossim 0.80).
1,2-DMH produced roughly equal amounts of T > C/A > G
(33%) and C > T/G > A (42%) and its signature did not resemble
patterns produced by other alkylating agents. Of note, the temo-
zolomide mutational pattern was not like COSMIC Signature 11
that had been previously associated with this treatment in
neuro-oncology tumors. Instead, the C > T/G > A component
of the mutation pattern of 1,2-DMH bears a striking resemblance
to the C > T/G > A component of Signature 11 (cossim 0.89), tall-
est peaks at NpCpC and NpCpT, and is the only compound in
this family to do so. The C > T/G > A component of DES and
DMS is different with the tallest peaks at ApCpA, ApCpT,
and CpCpT.
The predominance of T > C/A > G and C > T/G > A in the sig-
natures of alkylating agents may be a consequence of DNA
repair processes in iPSCs. O-alkylating DNA damage is usually
repaired by direct reversal. Mammalian alkylguanine-DNA-trans-
ferases (AGTs) transfer the alkyl group fromO-alkylated bases to
a receptor cysteine residue with the AGT protein. The process is
more efficient for O6-alkylguanine than for O4-alkylthymine and
O2-alkylthymine (Jenkins et al., 2005). Thus, the signatures
observed with ENU and MNU, which are more likely to form
O-alkylations, may reflect a greater persistence of O-alkylthy-
mine adducts that subsequently result in T > C/A > G transitions.
By contrast, DMS and DES are stronger N-alkylators, and
although they are also O-alkylators, O-alkylthymine has not
been reported for this group (Jenkins et al., 2005). Hence, their
signatures are possibly the consequence of mis-replication of
persistent O6-alkylguanine mis-read as adenine with insertion
of thymine on the opposite strand resulting in excess of C >
T/G > A transitions.
Interestingly, 1,2-DMH presents an indel phenotype of C dele-
tions often flanked by thymine. Of 21 such indels, 20 were at
poly-T tracts of 4–8 bp (Figure 6D). Its substitution signature
has an excess of C > T mutations at CpTs that are also enriched
at poly-T tracts (Figure 6D). We posit that O6-alkylation by
1,2-DMH occurs on guanines at the end of poly-A tracts (equiv-
alent to cytosines abutting poly-Ts). Damage resolution results in
two different outcomes: O6-meG pairs with thymine resulting in
a G > A/C > T substitution or its immediate neighbors (or indeed
itself) are excised similar to an insertion-deletion loop resulting in
a single nucleotide deletion (Figure 6D).
Insights into Mutational Mechanisms of Platinum
Complexes
The substitution signatures of the two platinum complexes were
dominated byG > A/C > Twith a high degree of similarity (cossim
0.95). The cisplatin signature was very similar to that in MCF10A
and HepG2 cells (Boot et al., 2018). The G > A transitions
occurred predominantly at GpGpG or ApGpG sequences (equiv-
alent to C > T at CpCpC and CpCpT).
We also report double-substitution signatures of the platinum
complexes, namely AG > TT and GA > TT. Cisplatin and carbo-
platin form intrastrand crosslinks at purines (e.g., ApG, GpA,
GpG) and a mispairing of such crosslinks with AA (Strauss,
2002) would result in TT mutations. Thus, misreplication acrossuninformative sites may be the driving force behind fixation of
double-substitutions.
Both compounds produced indel patterns, although only
the cisplatin signature reached significance (Figure 5C). We
postulate that error-prone excision repair of intrastrand cross-
links can result in ‘‘collateral damage’’ with indels of nearby
nucleotides.
Accordingly, primary DNA damage associated with platinum
complexes may be enhanced at GpG nucleotides but subse-
quent cellular attempts at resolving intrastrand crosslinks cre-
ates alternativemutagenic outcomes.Whether through crosslink
repair, error-prone excision repair, or translesion synthesis, there
are diverse signatures associated with platinum compounds.
Mutagenesis by Other Compounds
Human exposure to plant extracts containing aristolochic acid
involves exposure to at least two structurally related genotoxic
compounds, AAI and aristolochic acid II (AAII). Both compounds
gave rise to mutational signatures but only the former resembled
that seen in human cancers associated with aristolochic acid
exposure (Signature 22; cossim 0.99). This signature is highly
reproducible across multiple human tumor sites (urothelial, liver)
and at least two in vitro cellular systems (Nik-Zainal et al., 2015;
Poon et al., 2015).
Four agents (cyclophosphamide, furan, N-nitrosopyrrolidine,
and MX) form cyclic adducts with DNA bases, including
1,N2-dG, 3,N4-dC, and 1,N6-dA. However, their signatures
were distinctly different. This may reflect differentially domi-
nating adducts in each case or be because structurally dissimilar
cyclic adducts formed at the same binary positions in DNA have
different mutational consequences.
Overall our study has examples of agents with similar struc-
tures and/or mechanisms of action having similar signatures
(cisplatin and carboplatin; temozolomide, MNU, and ENU;
DMS and DES; DBA, BaP, and 5-methylchrysene), but also ex-
amples of distinctly different signatures arising from closely
related compounds (1,6-DNP and 1,8-DNP; AAI and AAII). There
are also intriguing examples of dissimilar agents with similar sig-
natures: PhIP and BaP/BPDE (cossim 0.95); MX and benzidine
(cossim 0.96); AAI and the TA-AT component of the DBP and
DBPDE signatures (cossim 0.96).
Relationships between Mutagen-Derived and Cancer-
Derived Signatures
We compared our experimentally generated mutational signa-
tures with those derived from human cancers. To ensure that
the analysis was not biased by prior assumptions of pre-defined
consensus mutational signatures, we revisited mutational signa-
ture extraction of 2,577 whole cancer genomes (unpublished
data). Tissue-specific signature extractions were performed,
identifying 196 independent signatures in 21 tissue types. We
expect some signatures to be similar between cancer types
(e.g., Signature 1 is age-associated and Signatures 2 and 13
are associated with APOBEC activity).
The strongest similarities observed are between the in vitro
AAI signature and liver and kidney cancer signatures (cossim
0.98 and 0.94, respectively) (Figure S3B) associated with expo-
sure to AAI. There was also concordance between DBP andCell 177, 821–836, May 2, 2019 831
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DBPDEwith the same signatures (range, 0.86–0.96) (Figure S3B).
Asmentioned earlier, this is likely because of similar presumptive
adduct formation on adenines by these agents and not because
of human exposure to DBP/DBPDE.
The SSR signature shows greatest resemblance to the UV sig-
natures in skin tumors. Signatures from PAHs (DBA, DBADE,
DBAC, BaP, BPDE, and 5-methylchrysene) show greatest
similarity to the lung cancer signature associated with tobacco
smoking (range, 0.84–0.95) (Figure S3B). Many chemical com-
pounds likely contribute to the carcinogenicity of tobacco
smoke. The contributions of each PAH to parts of COSMIC
Signature 4 can be seen, including a distinct T > A/A > T peak
at CpTpG, identical to that observed with DBP and DBPDE.
We can now also attribute double-substitution and indel compo-
nents of tobacco-smoke mutagenesis to BaP, DBA, and their
diol-epoxides, BPDE and DBADE (Figures 4C and 5B).
Other signatures have weaker relationships with some cancer
signatures and must be interpreted with caution. They
include nitro-PAHs, alkylating agents, heterocyclic and aromatic
amines, and drug therapies. Of interest, our cisplatin and
carboplatin signatures show concordance with a signature ex-
tracted from myeloid tumors in patients that had received
chemotherapy.
Last, the ubiquitous background signature present across the
control samples is similar to COSMIC Signature 18, previously
hypothesized to be due to ROS. Indeed, many cancer types
also show Signature-18-like patterns. A signature associated
with defective MUTYH, a glycosylase that excises 8-oxoG from
DNA, has also been shown to strongly resemble Signature 18
(Pilati et al., 2017).
Impact of DNA Repair on Mutational Signatures of
Environmental Mutagens
The experiments were performed in a single cell line, so there
was identical availability of DNA repair and/or replicative path-
ways for all treatments.We evaluated their mechanistic contribu-
tion to the mutational signatures through analyses of genome
topography.
Despite considerable nucleotide level variation, there were
high levels of chromosomal stability with few structural variants
across all 324 daughter subclones. Therefore, in our system,
DDR is robust with little tolerance for mutagenesis initiated byFigure 7. Strand Asymmetries and Genomic Distributions of Mutagen
(A) Transcriptional strand asymmetry of 53 mutagen substitution signatures in 6 c
***q value % 0.001. Pearson’s chi-square test with multiple test correction.
(B) Transcriptional strand asymmetry across RTDs of four selected agents.
(C) Schematic illustration on efficiency of DNA repair along RTD, contrasting mut
mutagenesis caused by DBADE forming N2-G adducts (bottom). Guanine-associa
to be enriched in early RTD. Hence, there is a negative gradient of an excess of da
of DBADE damage results in a steeper gradient. Fortunately, DNA repair is also
guanine-associated damage caused by ROS (cyan line, top). Likewise, TC-NER is
lines, bottom). For the culture-related signature (top), BER and MMR must be ope
distribution observed given by the difference between the red and cyan lines (gra
late RTD in all subclones. For the DBADE signature, TC-NER must be fully operat
(blue line) and non-transcribed strand (orange line), culminating in the mutati
respectively. The difference in substitution density between non-transcribed str
replication regions than in late ones. This is observed consistently for many PAH
See also Figures S6 and S7.double-strand-breaks (DSB). This reinforces work by others
exploring DNA repair pathways in stem cells that found DDR
and DSB repair to be intact.
Replicative strand asymmetry was not observed in any signa-
ture. Replication is less likely to play an influential role in repair of
exogenous damage, and more likely to impact intrinsic muta-
tional processes, as evidenced by strong replication strand
asymmetry seen for endogenous processes such as APOBEC-
related mutagenesis and MMR deficiency (MMRd) (Morganella
et al., 2016; Zou et al., 2018).
Across replication timing domains (RTD), mutation densities of
many signatures mirrored their expected distribution when cor-
rected for the reference genome trinucleotide content and for
the sequence context predilection (Figure S6).
We found marked transcriptional strand asymmetry for some
mutagens, although effect sizes were variable (Figures 7A and
S7). Tobacco-related compounds displayed exceptional strand
bias particularly in their predominant mutation class (G > A/C >
T or T > A/A > T). 6-Nitrochrysene, selected drug therapies,
ENU, and AAI also demonstrated transcriptional strand bias,
implicating the activity of TC-NER in the repair of damage by
these mutagens. Of note, SSR did not show transcriptional
strand asymmetry, as observed previously in MEFs (Nik-Zainal
et al., 2015). This is likely due to the extremely short experimental
UV exposure (8 s), in contrast to what transpires in vivo.
We assessed transcriptional strand asymmetry and found that
it was more marked in early RTD than in late RTD particularly for
compounds such as tobacco-related mutagens, e.g., BPDE.
This was also observed for cancer-derived signatures associ-
ated with tobacco smoking. It suggests that there is greater
TC-NER activity in early RTD than in late RTD in human cells in
general. In fact, the gradient from early to late is steeper in the
in vitro system suggesting that TC-NER is fully functional and
operating to the same level, if not to a higher level, in iPSCs as
in vivo (Figures 7B and 7C).
Finally, the background signature of cells grown in culture had
a distribution that is more typical of cancer-derived signatures,
with more mutations in late RTD (Figure S6). Unlike the short
duration of exposure to environmental agents in vitro, the cells
have had a more uniform and continuous exposure to ROS in
culture. Additionally, apart from the components of base exci-
sion repair that are required to fix free radical damage, a criticalSignatures
hannels. Asterisks indicate significant bias. *q value% 0.05; **q value% 0.01;
agenesis during culture/expansion of cells in vitromainly due to ROS (top) with
ted DNA damage (red lines) is more likely to occur at GC-rich regions that tend
mage in early RTDs for both of these forms of DNA damage, although high level
often more efficient in early RTDs. BER and MMR contribute to the repair of
involved in the repair of DBADE-associated guanine adducts (blue and yellow
rational and highly efficient particularly in the early RTD in order to achieve the
y zone). This results in a final distribution that has an excess of mutagenesis in
ional because the gradient of substitutions is different between the transcribed
onal distributions across RTD shown in deep purple and light purple lines,
and (deep purple line) and transcribed strand (light purple) is greater in early
s and is also in cancer-derived signatures.
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player in maintaining this gradient from early to late RTD is MMR
(Supek and Lehner, 2015). MMR-deficient tumors have more
mutations in early RTD. Thus, if MMR was not fully competent
in iPSCs, we would not see more mutations in late RTD in the
background signature.
In summary, DDR, DSB repair, MMR, and TC-NER are fully
operative in this cell system. A primary adduct can result in
many different mutation outcomes, dependent on which repair
pathways respond to the pre-mutagenic state.
DISCUSSION
We have presented a unique, comprehensive experimental and
analytical dataset, documenting the effects of known or sus-
pected environmental mutagens in a single stem cell line. There
is a mutational process present in all subclones indicative of
stresses irrespective of treatment. Given the identical availability
of DNA repair pathways, any additional mutational pattern seen
can be attributed to DNA damage associated with each agent.
Notably, the effect size associatedwith each treatment is var-
iable. Here, we have measured how damaging each environ-
mental mutagen is at comparable levels of cytotoxicity
(Figure 2D shows the relative mutagenic capability for each
treatment in generating substitution, double-substitution, or
indel signatures).Many signatures for which epidemiological re-
lationships are described (UV with melanoma, smoking with
lung cancer, and aristolochic acid with urothelial cancers) are
attributed to agents that have large effect sizes. For agents
with smaller effect sizes, it has been or will be challenging to
discern a signal in primary human tumors given the noise from
an uncontrolled setting (including multiple endogenous signa-
tures and variable exposure in different people). Thus, it may
be more difficult to detect epidemiological relationships with
environmental exposures where the mutagenic signal is weak.
Nonetheless, this systematic exercise provides us with a first,
extensive resource of a priori signatures. The added knowledge
may uncover evidence of environmental exposures in human
cancers, aiding epidemiological investigations into new causes
of cancer. However, thismust be donewith caution, because de-
pending on the mathematical methods used, supervised fitting
of these or other mutational signatures could lead to falsely sug-
gesting exposures where there have not been any. This is
important to stress as it may have important legal implications
for industries where some of these agents may be occupational
exposures.
Could there be differences if these experiments were repeated
in different cell types? Perhaps. There may be differences in
mutational signatures incurred by normal, primary cells of spe-
cific tissues, and differences if similar experimentswere conduct-
ed in cancer cell lines. DNA damage and, almost certainly, DNA
repair could be tissue-dependent. One would also anticipate
differences in mutational outcomes when performed on diverse
DNA repair defective cellular backgrounds. Notwithstanding,
an important point for this study was to use a single cell line
with a relatively unmutilated genome as a primary canvas from
which to delineate the signature outcomes of environmental
agents. Having a cell line where tissue-specific effects and/or
selection would not strongly influence the mutagenic outcome834 Cell 177, 821–836, May 2, 2019was important. Thus, we sought to use an undifferentiated normal
cell line to generate a reference set of mutation patterns of envi-
ronmental mutagens. Human iPSCs have potential for directed
differentiation into different tissues in the future and for compara-
bility with other undifferentiated cell lines and/or differentiated tis-
sue-specific 3D cultures. However, for agents that cause hefty
mutagenesis (e.g., UV, PAHs, AAI), damage is probably so exten-
sive that the signal may turn out to be essentially the same no
matter what system is used.
Finally, we have gained insights into the mechanisms of muta-
genesis for several environmental agents, including putative
fixation of double-substitutions and indels, and extended our
understanding of the contributions of DNA repair pathways
(direct reversal, TC-NER, MMR) that are likely operational in
iPSCs. Indeed, the absence of rearrangement and copy-number
signatures suggests that DDR and cell-cycle checkpoint activity
are functioning vigorously, with minimal tolerance of DSBs in
sensitive stem cells.
We have demonstrated an assortment ofmutational outcomes
arising from environmental exposures in a normal stem cell
type. The systematic experimental process and standardized
analytical steps in this study permits comparability within and
across agent families, providing a foundation on which to build
further experiments. In order to gain further insights into the
mechanisms of mutagenesis, future studies could explore envi-
ronmental mutagenesis on selected DNA repair defective
backgrounds.
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Szeltner, Z., Tusnády, G.E., Csabai, I., et al. (2016). A comprehensive survey of
the mutagenic impact of common cancer cytotoxics. Genome Biol. 17, 99.
Thibodeau, S.N., Bren, G., and Schaid, D. (1993). Microsatellite instability in
cancer of the proximal colon. Science 260, 816–819.
Thomas, N.E., Alexander, A., Edmiston, S.N., Parrish, E., Millikan, R.C., Ber-
wick, M., Groben, P., Ollila, D.W., Mattingly, D., and Conway, K. (2004).
Tandem BRAF mutations in primary invasive melanomas. J. Invest. Dermatol.
122, 1245–1250.
Tran, H.T., Keen, J.D., Kricker, M., Resnick, M.A., and Gordenin, D.A. (1997).
Hypermutability of homonucleotide runs inmismatch repair and DNA polymer-
ase proofreading yeast mutants. Mol. Cell. Biol. 17, 2859–2865.
Walker, B., Jr., and Gerber, A. (1981). Occupational exposure to aro-
matic amines: benzidine and benzidine-based dyes. Natl. Cancer Inst.
Monogr., 11–13.
Wohak, L.E., Krais, A.M., Kucab, J.E., Stertmann, J., Øvrebø, S., Seidel, A.,
Phillips, D.H., and Arlt, V.M. (2016). Carcinogenic polycyclic aromatic hydro-
carbons induce CYP1A1 in human cells via a p53-dependent mechanism.
Arch. Toxicol. 90, 291–304.
Yang, M. (2011). A current global view of environmental and occupa-
tional cancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 29,
223–249.
Ye, K., Schulz, M.H., Long, Q., Apweiler, R., and Ning, Z. (2009). Pindel: a
pattern growth approach to detect break points of large deletions andmedium
sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871.
Zhivagui, M., Korenjak, M., and Zavadil, J. (2017). Modelling Mutation Spectra
of Human Carcinogens Using Experimental Systems. Basic Clin. Pharmacol.
Toxicol. 121 (Suppl 3 ), 16–22.
Zou, X., Owusu, M., Harris, R., Jackson, S.P., Loizou, J.I., and Nik-Zainal, S.
(2018). Validating the concept of mutational signatures with isogenic cell
models. Nat. Commun. 9, 1744.
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-phospho CHK2 (Thr68) Cell Signaling Technology Cat#2661; RRID:AB_331479
Mouse monoclonal anti-phospho p53 (S15) Cell Signaling Technology Cat#9286; RRID:AB_331741
Mouse monoclonal anti-p21 BD Biosciences Cat#556431; RRID:AB_396415
Rabbit monoclonal anti-phospho Histone
H2A.X (S139)




Chemicals, Peptides, and Recombinant Proteins
rat liver S9 MolTox 11-101
hamster liver S9 MolTox 15-03SL.5
(±)-anti-Benzo[a]pyrene-7,8-dihydrodiol-
9,10-epoxide; BPDE
Synthesized at the Institute of
Cancer Research (London, UK);





Synthesized by the Biochemical
Institute for Environmental Carcinogens
(Grosshansdorf, Germany); Wohak





Synthesized by the Biochemical Institute
for Environmental Carcinogens
(Grosshansdorf, Germany); Wohak
et al., 2016. https://doi.org/10.1007/
s00204-014-1409-1
CAS: 153926-04-6
1,2-Dimethylhydrazine Sigma-Aldrich D161802; CAS: 540-73-8
1,4-Benzoquinone Santa Cruz sc-202873; CAS: 106-51-4
1,6-Dinitropyrene Sigma-Aldrich 284327; CAS: 42397-64-8
1,8-Dinitropyrene Sigma-Aldrich 284319; CAS: 42397-65-9
1-Nitropyrene Sigma-Aldrich N22959; CAS: 5522-43-0
2,6-Dimethylaniline Sigma-Aldrich D146005; CAS: 87-62-7
2-amino-1-methyl-6-phenylimidazo[4,5-b]
pyridine; PhIP
Synthesized at the Biochemical Institute
for Environmental Carcinogens
(Grosshansdorf, Germany);





Toronto Research Chemicals A606600; CAS: 77500-04-0
2-amino-3-methyl-9H-pyrido[2,3-b]
indole; MeAaC
Toronto Research Chemicals A617500; CAS: 68006-83-7
2-amino-3-methylimidazo[4,5-f]quinoline; IQ Toronto Research Chemicals A616500; CAS: 76180-96-6
2-Naphthylamine Santa Cruz sc-209239; CAS: 91-59-8
2-Nitrofluorene Sigma-Aldrich N16754; CAS: 607-57-8
2-Nitrotoluene Sigma-Aldrich 438804; CAS: 88-72-2
3-Nitrobenzanthrone Synthesized as described by
Arlt et al., 2002.
PMID: 12419844
CAS: 17117-34-9
4,4’-Methylene(2-chloroaniline) Tokyo Chemical Industry Co., Ltd. M0609; CAS: 101-14-4
(Continued on next page)
Cell 177, 821–836.e1–e7, May 2, 2019 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
4-Aminobiphenyl Sigma-Aldrich A2898; CAS: 92-67-1
5-Methylchrysene Sigma-Aldrich BCR081R; CAS: 3697-24-3
6-Nitrochrysene Sigma-Aldrich BCR309; CAS: 7496-02-8
7H-Dibenzo[c,g]carbazole Sigma-Aldrich BCR266; CAS: 194-59-2
Acetaldehyde Sigma-Aldrich W200301; CAS: 75-07-0
Acrolein Sigma-Aldrich 89116; CAS: 107-02-8
Acrylamide Sigma-Aldrich 01700; CAS: 79-06-1
Aflatoxin B1 Sigma-Aldrich A6636; CAS: 1162-65-8
Aristolochic acid I Synthesized at the Institute of Cancer
Research, London, UK. https://doi.org/
10.1007/s00204-016-1808-6.
CAS: 313-67-7
Aristolochic acid II Synthesized at the Institute of Cancer
Research, London, UK. https://doi.org/
10.1007/s00204-016-1808-6.
CAS: 475-80-9
AZ20 Tocris Bioscience 5198; CAS: 1233339-22-4
AZD7762 Cayman Chemical 11491; CAS: 860352-01-8
Benzidine Santa Cruz sc-214583; CAS: 92-87-5
Benzo[a]pyrene Sigma-Aldrich B1760; CAS: 50-32-8
Bleomycin Lundbeck, Ltd. Lundbeck, Ltd.; CAS: 11056-06-7
Cadmium chloride Sigma-Aldrich 202908; CAS: 10108-64-2
Camptothecin Cambridge Bioscience C0150; CAS: 7689-03-4
Carboplatin Johnson Matthey, UK Johnson Matthey, UK; CAS: 41575-94-4
Catechol Alfa Aesar 10164; CAS: 120-80-9
Cisplatin Sigma-Aldrich P4394; CAS: 15663-27-1
Cobalt(II) chloride Sigma-Aldrich C8661; CAS: 7646-79-9
Cyclophosphamide Sigma-Aldrich C7397; CAS: 50-18-0
Dibenz(a,j)acridine Sigma-Aldrich BCR154; CAS: 224-42-0
Dibenz[a,h]anthracene Synthesized by the Biochemical Institute
for Environmental Carcinogens; Wohak
et al., 2016. https://doi.org/10.1007/
s00204-014-1409-1
CAS: 53-70-3
Dibenzo[a,l]pyrene Synthesized by the Biochemical Institute
for Environmental Carcinogens; Wohak
et al., 2016. https://doi.org/10.1007/
s00204-014-1409-1
CAS: 191-30-0
Diethyl sulfate Alfa Aesar L14291; CAS: 64-67-5
Dimethyl sulfate Sigma-Aldrich D186309; CAS: 77-78-1
Ellipticine (5,11-dimethyl-6H-pyrido
[4,3-b]carbazole)
Calbiochem 324688; CAS: 519-23-3
Etoposide Cayman Chemicals 12092; CAS: 33419-42-0
Formaldehyde Sigma-Aldrich F1635; CAS: 50-00-0
Furan Sigma-Aldrich 185922; CAS: 110-00-9
Glycidamide Sigma-Aldrich 04704; CAS: 5694-00-8
Hydrogen peroxide Sigma-Aldrich H1009; CAS: 7722-84-1
Lead(II) acetate Alfa Aesar A11746; CAS: 301-04-2
Lead(II) nitrate Alfa Aesar A16345; CAS: 10099-74-8
Mechlorethamine; nitrogen mustard ApexBio B1785; CAS: 51-75-2
Melphalan Sigma-Aldrich M2011; CAS: 148-82-3
Methyl methanesulfonate Sigma-Aldrich 129925; CAS: 66-27-3
Methyleugenol Sigma-Aldrich 284424; CAS: 93-15-2
(Continued on next page)
e2 Cell 177, 821–836.e1–e7, May 2, 2019
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Mitomycin C Santa Cruz sc-3514B; CAS: 50-07-7
Mutagen X (3-Chloro-4-(dichloromethyl)-
5-hydroxy-2(5H)-furanone)
Toronto Research Chemicals C365665; CAS: 124054-17-7
N-Ethyl-N-nitrosourea; N-Nitroso-
N-ethylurea
Sigma-Aldrich N3385; CAS: 759-73-9
Nickel(II) chloride Alfa Aesar B22085; CAS: 7791-20-0
N-Methyl-N’-nitro-nitrosoguanidine Tokyo Chemical Industry Co., Ltd. M0527; CAS: 70-25-7
N-Methyl-N-nitrosourea; N-Nitroso-
N-methylurea
Sigma-Aldrich N1517; CAS: 684-93-5
N-Nitrosopyrrolidine Sigma-Aldrich 158240; CAS: 930-55-2
o-Anisidine Sigma-Aldrich A88182; CAS: 90-04-0
Ochratoxin A Sigma-Aldrich O1877; CAS: 303-47-9
Olaparib; AZD2281 Cayman Chemicals 10621; CAS: 763113-22-0
o-Toluidine Sigma-Aldrich 185426; CAS: 95-53-4
Peroxynitrite; Peroxynitrous acid,
sodium salt
Calbiochem 516620; CAS: 14042-01-4
Potassium bromate Alfa Aesar A18258; CAS: 7758-01-2
Potassium chromate Santa Cruz sc-203351; CAS: 7789-00-6
Propylene oxide Sigma-Aldrich 82320; CAS: 75-56-9
Semustine; Methyl-CCNU Santa Cruz sc-391062; CAS: 13909-09-6
Sodium (meta)arsenite Fluka discontinued; CAS: 7784-46-5
Styrene oxide Sigma-Aldrich S5006; CAS: 96-09-3
Sudan I (1-phenylazo-2-hydroxy-
naphthalene)
Sigma-Aldrich 51383; CAS: 842-07-9
Temozolomide Sigma-Aldrich T2577; CAS: 85622-93-1
Critical Commercial Assays
Deep Blue Cell Viability Kit Biolegend Cat# 424702
Deposited Data
Raw and analyzed data This paper EGAD00001004583
Mutation data This paper http://doi.org/10.17632/m7r4msjb4c.2
Experimental Models: Cell Lines
Human iPSC line Wellcome Trust Sanger Institute N/A
Software and Algorithms
Graphpad Prism Graphpad SCR_002798
R R Core Team https://www.R-project.org/
R codes This paper https://github.com/xqzou/Cell_MutagenSig
CaVEMan Jones et al., 2016 http://cancerit.github.io/CaVEMan/
Pindel Raine et al., 2015; Ye et al., 2009 http://cancerit.github.io/cgpPindel
BRASS Nik-Zainal et al., 2016 https://github.com/cancerit/BRASS
IntersectBed Quinlan and Hall, 2010 https://bedtools.readthedocs.io/en/latest/
content/tools/intersect.html
Other
Resource website for the mutagen
signatures
This paper Mutational Signature website, SIGNAL,
that is in preparationCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, andwill be fulfilled by the corresponding authors Serena Nik-Zainal
(Lead contact, sn206@cam.ac.uk) and David H. Phillips (david.phillips@kcl.ac.uk).Cell 177, 821–836.e1–e7, May 2, 2019 e3
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The human iPSC line used for this study was derived at the Wellcome Trust Sanger Institute (Hinxton, UK). The use of this cell line
model was approved by Proportionate Review Sub-committee of the National Research Ethics (NRES) Committe NorthWest - Liver-
pool Central under the project ‘‘Exploring the biological processes underlying mutational signatures identified in induced pluripotent
stem cell-lines (iPSCs) that have been genetically modified or exposed tomutagens’’ (ref: 14.NW.0129). It is a long-standing iPSC line
originally derived from a patient with alpha-1-antitrypsin deficiency, for which one of the alleles was corrected. The cell line is diploid
and does not have any known driver mutations. It does carry a balanced translocation between chromosomes 6 and 8. It is stably
growing in culture and does not acquire a vast number of karyotypic abnormalities. This is confirmed through theWGS data reviewed
of all 328 subclones. Cell culture reagents were obtained from Stem Cell Technologies, unless otherwise indicated. Cells were
routinely cultured and treated on Vitronectin XF-coated plates [10-15 mg/mL] in TeSR-E8medium at 37C in 5%CO2, with the excep-
tion of cells treated in the presence of S9mix which were seeded onMatrigel-coated plates (Corning). Mediumwas replenished daily
and cultures were passaged at 80%confluency every 3–4 days usingGentle Cell Dissociation Reagent. Frozen stockswere prepared
in Knockout Serum Replacement (GIBCO) supplemented with 10% DMSO and stored in liquid nitrogen.
METHODS DETAILS
Treatment with DNA damaging agents and DDR inhibitors
The agents examined in this study are listed in Table S1, which includes information on sources, preparation of working stocks and
treatment duration. Compounds were dissolved in appropriate solvents where necessary, as shown, and diluted in growth media
immediately prior to treating cells. Cells were exposed to treatment media or solvent control media for up to 24 hr, then growth media
was replaced and replenished daily as necessary. Compounds requiring cytochrome P450-mediated metabolic conversion to
DNA-reactive intermediates were also tested with the inclusion of S9 mix, which consisted of 0.25% S9 fraction from Aroclor-
1254-induced male Sprague Dawley rat liver (#11-101) or male Golden Syrian hamster liver (#15-03SL.5) (Moltox), 3 mM NADP
(Roche) and 15 mM DL-isocitric acid trisodium salt hydrate (Sigma) in media. Cells were exposed to compounds in the presence
of S9 mix for 3 hr, then replaced with fresh growth media. For nonchemical agents, cells were treated as follows: cells were exposed
in PBS to simulated solar radiation (SSR) using a 300W-16S xenon arc solar UV simulator (Solar Light, Glenside, USA), as described
recently (Lawrence et al., 2018), kindly provided by Professor Antony Young (King’s College London). The SSR output consisted
of % 10% UVB (295–315 nm) and R 90% UVA (315–400 nm). Cells were gamma-irradiated in media using a Noridon
GC-1000S v2.9 cell irradiator, which contains a caesium-137 source delivered at a dose rate of 250 ± 0.59% Gy/hour (access
provided by Dr Mahvash Tavassoli, King’s College London).
Assessment of cell viability
Cells were seeded for viability assays on 96-well plates, ensuring that cells were dissociated into clumps of10–25 cells in size prior
to seeding. For gamma irradiation, cells were seeded into 12.5-cm2 flasks. Cells were treated at 5%–10% confluency with a range of
concentrations (R6) for each agent, in order to establish dose-response curves spanning 0%–100% cytotoxicity, where possible,
with each treatment condition tested inR 3 technical replicates. Following the appropriate treatment duration, cells weremaintained
in growth medium to allow cell division and processing of DNA damage. At 72 hr after treatment initiation, cell viability was quantified
using the Deep Blue Cell Viability Kit (Biolegend), which measures the reduction of reazurin to fluorescent resorufin by viable cells.
Fluorescence (Ex530/Em590) was measured using a plate reader. Data are presented as the amount of fluorescence of treated cells
relative to that of control (media only or solvent-treated) cells and are representative of at least three independent experiments. IC50
values were calculated using Prism 7 software.
Western blotting
Cells were seeded into 12-well plates and treated with a range of concentrations of each agent, as described above, including a
negative control (media only or solvent-treated). At 8 hr or 24 hr post-treatment, cells were washed with PBS and lysed (62.5 mM
Tris [pH 6.8], 1 mM EDTA, 2% SDS, 10% glycerol, 1X Halt Protease Inhibitor Cocktail (Thermo Scientific)). b-Mercaptoethanol
(0.1% v/v) and bromophenol blue (0.01% w/v) were added to each lysate prior to denaturation at 95C for 5 min. Cells treated
with hydrogen peroxide or gamma irradiation were also harvested 2 or 4 hr post-treatment. Equal amounts of protein (10–20 mg)
were loaded onto 4%–12% Bis-Tris gels (NuPAGE; #NP0336 Invitrogen), separated by SDS-PAGE and transferred onto nitrocellu-
lose membranes. Each gel was also loaded with a lysate from cells treated with cisplatin (3.125 mM; 24 h) as a positive control for
DDR protein expression. Membranes were incubated with primary antibody (anti-phospho-CHK2 (T68) (#2661 Cell Signaling
Technologies), anti-phospho-p53 (S15) (#9286 Cell Signaling Technologies), anti-p21 (#556431 BD PharMingen), anti-phospho-
Histone H2A.X (S139) (#9718 Cell Signaling Technologies) and anti-GAPDH (#MAB374 Millipore)) followed by species-specific
horseradish peroxidase-conjugated secondary antibody (Bio-Rad) and bands were detected by chemiluminescence.e4 Cell 177, 821–836.e1–e7, May 2, 2019
Cell treatment and cloning for WGS
Cells were treated with each agent at a concentration resulting in 40%–60% cytotoxicity, in parallel with cells treated with media only
or appropriate solvent control. Additionally, cells were treated with some compounds at a concentration giving > 80% cytotoxicity.
Following treatment, cells were cultured for7 days to recover and expand, then frozen stocks were prepared. To isolate single cell
clones, treated cell populations were dissociated into single cell suspensions using Accutase (Innovative Cell Technologies) and
seeded at limiting dilution on 96-well plates in the presence of 10 mM Y-27632 (Sigma). Medium was replaced daily (without
Y-27632) until clones were established (7 – 10 days), then 6 clones were passaged from each treatment condition to 6-well plates
for expansion. Frozen stocks were prepared for each clone in addition to a cell pellet for DNA isolation. The IncuCyte was used to
ensure that each subclone had arisen from a single cell. This was done by screening images taken every 6 hours over 10-12 days
to ensure that: 1) only one single clone is in the well before collection; 2) the single clone does not derive from the ultimate fusion
of two clones (at any time point); 3) the single clone derives from a single-cell, defined by the observation of the first division of
the cell into two cells. A minimum of three experienced operators reviewed the clones and were required to agree on their
observations.
DNA extraction and library preparation
Samples were quantified with Biotium Accuclear Ultra high sensitivity dsDNA Quantitative kit using Mosquito LV liquid platform,
Bravo WS and BMG FLUOstar Omega plate reader and cherrypicked to 200ng / 120ml using Tecan liquid handling platform.
Cherrypicked plates were sheared to 450bp using a Covaris LE220 instrument. Post sheared samples were purified using Agen-
court AMPure XP SPRI beads on Agilent Bravo WS. Libraries were constructed (ER, A-tailing and ligation) using ‘NEB Ultra II
custom kit’ on an Agilent Bravo WS automation system. KapaHiFi Hot start mix and IDT 96 iPCR tag barcodes were used for
PCR set-up on Agilent Bravo WS automation system. PCR cycles include 6 standard cycles: 1) Incubate 95C 5 mins; 2) Incubate
98C 30 s; 3) Incubate 65C 30 s; 4) Incubate 72C 1 min; 5) Cycle from 2, 5 more times; 6) Incubate 72C 10 mins. Post PCR plate
was purified using Agencourt AMPure XP SPRI beads on Beckman BioMek NX96 liquid handling platform. Libraries were quan-
tified with Biotium Accuclear Ultra high sensitivity dsDNA Quantitative kit using Mosquito LV liquid handling platform, Bravo WS
and BMG FLUOstar Omega plate reader, then pooled in equimolar amounts on a Beckman BioMek NX-8 liquid handling platform
and finally normalized to 2.8 nM ready for cluster generation on a c-BOT and loading on requested Illumina sequencing platform.
Pooled samples were loaded on the X10 using 150 PE run length, sequenced to 30X coverage. The details of sequence coverage
for all clones and subclones are provided in Table S5.
Alignment and somatic variant-calling
Human reference genomeGRCh37/hg19was used for short reads alignment. CaVEMan (http://cancerit.github.io/CaVEMan/), Pindel
(http://cancerit.github.io/cgpPindel) andBRASS (https://github.com/cancerit/BRASS) were used to call somatic substitutions, indels
and rearrangements in all subclones, respectively. Variant allele fraction distribution for each daughter subclone was examined and a
filter of VAFR 0.2 was applied to substitutions and indels. Shared mutations among subclones were removed to obtain de novo so-
matic mutations after mutagen treatments. Table S2 summarizes the numbers of de novo mutations (substitutions, indels and
rearrangements) for all subclones.
QUANTIFICATION AND STATISTICAL ANALYSIS
Identification of background signatures
The mutational profiles of control subclones represent the pattern of background mutagenesis (background signatures). Each
control subclone has 250 substitutions, 10 indels and 1 double-substitution. We could neglect the background double-
substitution signature from mutagen-treated cells, as the number is close to zero. However, the background substitution and indel
mutagenesis are not negligible, we need to identify these signatures in controls in prior to characterize mutagen-associated
mutational signatures.
We used 96 and 29 channels to describe substitution and indel profiles, respectively. Hence, the substitution-to-channel ratio is
about 2.6, and the indel-to-channel ratio is about 0.34, less than 1. Indeed, this mutation-to-channel ratio affects the profile similarity
between control subclones. All the control subclones have very similar substitution profiles (cossim > = 0.9), while their indel profiles
show much less consistency (0.08 % cossim % 0.97). Hence, we use the mean of substitution profiles of 35 control subclones as
background substitution signature (Figure 3A). For background indel signature, we aggregated 35 control subclone indel profiles,
as shown in Figure 5A. To validate the control indel signature, we aggregated indels from treatments which show the same indel
burden as controls (and therefore unlikely to have signatures) (p value > 0.1) and indels from treatments which are likely to have sig-
natures (p value < 0.01), as shown in Figure S4. Indeed, aggregated control indel profile (Figure S4C) is almost identical (cosine
similarity = 0.99) to the aggregated indel profiles of no-indel-increase treatments (Figure S4D). In contrast, the cosine similarity
between control indel profiles and the aggregated indel profiles of treatments with p value < 0.01 (Figure S4B) is 0.78. This result
reinforces how the aggregated control indel profile present the full picture of the background indel mutagenesis.Cell 177, 821–836.e1–e7, May 2, 2019 e5
Characterization of mutagen-associated mutational signatures
Compared with control cells (no mutagen was applied to cells), mutagen-treated cells not only have background mutagenesis pre-
sent in the cell, but may also have additional mutagen-associated mutagenesis which increases the mutation burden in the cell
(Figure 1C):
Nsubclone =Nbackground +Nmutagen: (1)
Nsubclone is the number of mutations observed in mutagen-treated subclones. Nbackground and Nmutagen are the number of mutations
resulting from background and mutagen mutagenesis, respectively. The extra mutation burden Nmutagen
 
is mutagen-dependent–
determined by the specific damage ofmutagen onDNA and the downstream repair pathways. Different mutational process can result
in different combinations of mutational types, termed mutational signatures, which can be expressed as a K-vector. For example,











pkbackground = 1, and K is the number of mutation types (96 for substitutions and 29 for indels). Similarly, the mutational spectrum
(combinations of mutational types) of the extra mutation burden induced by mutagen treatment is defined as mutagen-associated











pkmutagen = 1. There are four steps to characterize
mutagen-associated mutational signatures, Pmutagen.
First, determining the increase of mutation numbers in subclones of mutagen-treated cells. In the present study, every treatment
has 2-4 subclones, so the average mutation burden of each treatment can be obtained. Based on 35 control subclones, we
constructed the distributions of means of 2, 3 and 4 control subclones using bootstrap resampling techniques. According to the con-
trol bootstrapping distribution, the p value of the mutation number for each mutagen treatment can be calculated, and followed by
multiple testing correction. Adjusted p value < 0.01 indicating a significant increase of mutation number was observed in a specific
mutagen treatment.
Second, measuring the distinction betweenmutation profile of control andmutagen subclone profiles. Themutation profile of con-











mkcontrol =Ncontrol, and m
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control is the mutation number observed in











mksubclone =Nsubclone, and m
k
subclone is the mutation number observed in mutation type k. We calculated the ‘‘signal-to-noise’’ ratio
(SNR) between control profiles and mutagen subclone profiles to identify if they have significant difference. Msubclone and Mcontrol
denote the means of the mutation profiles of mutagen subclones and control subclones, respectively; ssubclone and scontrol denote






The value of SNR depends on two components. One is related to signal kMsubclone Mcontrolk2
 
, which measures the averaged
Euclidean distance between the mutation profiles of mutagen subclones and control subclones. The other one is related to noise
smutagen + scontrol
 
, measuring the variability (consistency) of mutation profiles of subclones. A large value of SNR indicates that
the difference between the control subclones and mutagen-treated subclones is more likely to be distinguishable from their noises
and, therefore, themutagen-associated signature may be separated from the background signature. The threshold of SNRwe chose
to determine if a mutagen-treatment generates a signature is 2, corresponding to about 90% of mutagen profiles are different from
the centroid of control subclone profiles with p value < 0.1.
Third, extracting mutagen-associated mutational signatures by removing the background mutation profile from subclone muta-
tional profile for treatment with p value < 0.01 and SNR > = 2. The mutational profile of mutagen-treated subclones is a linear com-
bination of the mutational profile of background mutagenesis and the mutational profile of mutagen-associated mutagenesis:
Msubclone =Mbackground +Mmutagen =Nbackground 3Pbackground +Nmutagen 3Pmutagen: (3)
Without treating with mutagens, cells only accumulate mutations due to background mutagenesis, so the control mutation profile
represents the background mutation profile in control and all mutagen-treated subclones: MbackgroundyMcontrol, and
NbackgroundyNcontrol. Hence, one can readily derive, using Equation 3,
Pmutagen =
Msubclone Mcontrolð Þ
Nsubclone  Ncontrolð Þ : (4)e6 Cell 177, 821–836.e1–e7, May 2, 2019
Fourth, measuring the stability of mutational signatures. The stability of a signature is defined as the maximum value of cosine
similarity between mutational signatures extracted from each subclone for a given treatment. Stability > = 0.8 indicates a signature
was consistent in at least two subclones.
Double-substitution mutagenesis
Double substitutions are two substitutions adjacent to each other. With the increase of number of substitutions in a sample, the
likelihood of occurrence of two substitutions next to each other increase accordingly. The probability of observing at least one double
substitution in a sample is
PðNdoublesubstitutionR1Þ= 1 PðNdoublesubstitution = 0Þ : (5)
Ndoublesubstitution is the number of double substitutions observed in a sample. For each sample, the number of mutations and its
mutational profile are known. The 32-trinucleotide frequency in the reference genome can be obtained. For a sample with Nsub
substitutions, the probability of occurrence of the first mutation is P1 = 1. The second mutation can occur anywhere other than
the position of the first mutation and its neighbor positions. According to the trinucleotide of the first mutation and its neighbors,
the available positions Navailable positions
 
for the second mutation can be updated and, therefore, the probability of the second
mutation can be calculated by P2 =Navailable positions=Ntotal positions, where Ntotal positions is the total number of trinucleotides of the
second mutation in the genome. This calculation can continue for the last mutation in Nsub. Hence one can obtain
P Ndoublesubstitution = 0ð Þ=P1 3P2 3/3PNsub: (6)
There are 78 unique double-substitution types shown in Table S6.
Many fewer double substitutions were generated in subclones, compared with substitutions and indels. Hence, in order to
appreciate a double-substitutions signature in a pattern of 78 channels, we only consider the treatments which have more than
20 double-substitutions.
Genomic features of mutagen-associated signatures
The influence of several genomic features on the experimentally-generated mutational signatures was investigated, including repli-
cative and transcriptional strand bias, the distribution of mutations on replication-timing regions and methylation status on PAH
mutagenesis. Reference information of replicative strands and replication-timing regions were obtained from the ENCODE project
Repli-seq data (https://www.encodeproject.org/). The transcriptional strand coordinates were obtained from the footprints of protein
coding genes in the genome. CpG island coordinates were obtained from Gardiner-Garden’s work (Gardiner-Garden and Frommer,
1987). IntersectBed was used to identify mutations overlapping certain genomic features. Pearson’s chi-square test was used to
evaluate the significance of strand bias. All statistical analysis were performed in R. All plots were generated by ggplot2.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw sequencing data reported in this paper is EGA:EGAD00001004583. All mutation data can be
obtained on Mendeley: http://doi.org/10.17632/m7r4msjb4c.2.
R codes are available at https://github.com/xqzou/Cell_MutagenSig.
ADDITIONAL RESOURCES
The curated datawill become available for general browsing, down to individual subclone level fromour referenceMutational Signature
website, SIGNAL, that is in preparation.Cell 177, 821–836.e1–e7, May 2, 2019 e7
Supplemental Figures
(legend on next page)
Figure S1. Cell Viability andDDR Induction following Treatment of Human iPSCswith EnvironmentalMutagens, Related to Figure 1, Table S1,
and STAR Methods
Included are examples of agents that (A) induced DDR and had an associated mutational signature, (B) induced DDR but did not have an associated mutational
signature and (C) did not induce DDR and did not have an associated mutational signature. For viability assessment, cells were treated with the indicated
concentrations of mutagen (or solvent control) for either 2 h (BPDE, DBADE and DBPDE), 3 h (when rat liver S9 mix was included) or 24 h. Viability was measured
72 h following initiation of treatment using the Deep Blue Cell Viability Kit. Mean values are shown as% of control ± SD of at least 3 replicate experiments. Protein
expression of p-CHK2 (T68), p-p53 (S15), p21 and g-H2AX (S139) was assessed by western blotting. GAPDH served as a loading control. Cells were treated as
described above and lysed at 8 h or 24 h following initiation of treatment.
Figure S2. Using an IncuCyte to Follow Single-Cell-Derived Subclones, Related to STAR Methods
(A) Screening images taken every 6 hours over 10-12 days. (B) Variant allele frequency of subclones, 15 randomly selected subclones are shown. To remove
mutations present from potential polyclonal samples, a filter of VAF > = 0.2 was applied to substitutions and indels.
Figure S3. Comparison of Mutational Signatures between Cancer (In Vivo) and Mutagen (In Vitro), Related to Figure 3
(A) Cosine similarity between 30 COSMIC substitution signatures (https://cancer.sanger.ac.uk/cosmic/signatures) and mutagen substitution signatures.
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Figure S4. Identification of Background Indel Signatures, Related to Figure 5 and STAR Methods
(A–D) Comparing indel number obtained from mutagen treatments and controls, one can identify the treatments that do not generate indel signatures (p value >
0.1). The aggregated control indel profile (bottom left) shows high similarity (0.99) with the aggregated indel profile from treatments with p value > 0.1 (treatments
that do not manifest indel signatures, bottom right).
(legend on next page)
Figure S5. Indel Profiles of Mutagen-Associated Treatments with p Value < 0.01, Related to Figure 5
There are 41 treatments with a significant increase in indel numbers (P value < 0.01). Ten of them shown in Figure 5B have SNR > = 2, average indel number per
subclone > = 20 and stability > = 0.7. The other 31 treatments did not show clear signatures, because the increased number of indels in each subclone was
relatively low e.g., less than 10 above the baseline, and the number of subclones of each treatment is low (2-4). By distributing less than 20-40 indels into
29 channels, one is hardly able to appreciate a signature. Althoughwe do not have enough power to obtain full pictures of indel signatures for these 31 treatments,
some characteristic features are appreciable. For example, treatment of 3.125 mMcisplatin has T insertion in poly T tracks, which is similar to treatment of 12.5 mM
cisplatin. Treatments of PhIP with S9 at two concentrations all show distinct C deletions. Two radiation experiments, namely gamma irradiation and simulated
solar radiation, both show increased microhomology-mediated deletions, indicating additional double-stranded DNA breaks may be induced by radiations. For
PAHs, treatment with 5-methylchrysene (1.6 mM) +S9 induced additional C deletions; treatment with BaP (0.39 mM) +S9 has a similar profile to treatment with BaP
(2 mM) +S9 and BPDE (0.125 mM) (Figure 5B); treatment with DBA (75 mM) +S9 shows both increased T insertion and C deletion, similar to treatments with DBADE
(0.0313 mMand 0.109 mM). It seems that manymutagens from different groups are able to cause C deletions, such as potassium bromate (875 mM), AAI (1.25 mM),
MX (7 mM)with S9, 1,6-DNP (0.09 mM), 3-NBA (0.025 mM) and 6-nitrochrysene, indicating the damage on guanine can often result in C:G pair deletion. Thus for the
cohort described in this paragraph, indel signatures may well exist, but according to our conservative criteria we did not report these as signatures because the
current study is underpowered to be able to do this.
Figure S6. Distribution of Normalized Mutation Density across the Replication Timing Domains, Related to Figure 7
The G2/S phase was separated into ten replication timing domains. The expected distribution of mutations in replication timing regions was obtained through
simulation based on the signature profile and trinucleotide distribution. Red asterisk ‘‘*’’ marks the mutagen treatments having observed distribution (green bars)
different from simulated distribution (blue line).
Figure S7. Histogram of Mutation Density on Transcribed (Red) and Non-transcribed (Cyan) Strands of Treatments Having q Value % 0.01,
Related to Figure 7
Bars and error represent mean ± SEM of subclone observations.
